Tech Company Financing Transactions
Akribion Therapeutics Funding Round
Akribion Therapeutics, based in Zwingenberg, secured $8.3 million from Carma Fund, BMH Beteiligungs-Managementgesellschaft Hessen mbH and Bruker.
Transaction Overview
Company Name
Announced On
2/4/2025
Transaction Type
Venture Equity
Amount
$8,300,000
Round
Seed
Investors
Carma Fund (Lead Investor) (Martin Raditsch)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Darmstädter Straße 34-36
Zwingenberg, 64673
Germany
Zwingenberg, 64673
Germany
Phone
Email Address
Overview
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lukas Linnig
Browse more venture capital transactions:
Prev: 2/4/2025: Service Compression venture capital transaction
Next: 2/4/2025: Coolnis venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs